|
2021 Journal Article PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics eraRyder, Simon J., Love, Amanda J., Duncan, Emma L. and Pattison, David A. (2021). PET detectives: molecular imaging for phaeochromocytomas and paragangliomas in the genomics era. Clinical Endocrinology, 95 (1), 13-28. doi: 10.1111/cen.14375 |
|
2021 Journal Article [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3 |
|
2021 Journal Article Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluationArnfield, Evyn G., Thomas, Paul A., Roberts, Matthew J., Pelecanos, Anita M., Ramsay, Stuart C., Lin, Charles Y., Latter, Melissa J., Garcia, Peter L. and Pattison, David A. (2021). Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 48 (13), 4495-4507. doi: 10.1007/s00259-021-05456-3 |
|
2019 Journal Article Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocolIravani, Amir, Solomon, Benjamin, Pattison, David A., Jackson, Price, Ravi Kumar, Aravind, Kong, Grace, Hofman, Michael S., Akhurst, Tim and Hicks, Rodney J. (2019). Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol. Thyroid, 29 (11), 1634-1645. doi: 10.1089/thy.2019.0143 |
|
2019 Journal Article Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CTPattison, David A., MacFarlane, Lisa L., Callahan, Jason, Kane, Emma L., Akhurst, Timothy and Hicks, Rodney J. (2019). Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. EJNMMI Research, 9 (1) 15, 15. doi: 10.1186/s13550-019-0480-2 |
|
2017 Journal Article 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual InterpretationPattison, David A., Bozin, Michael, Gorelik, Alexandra, Hofman, Michael S., Hicks, Rodney J. and Skandarajah, Anita (2017). 18F-FDG–Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. Journal of Nuclear Medicine, 59 (5), 749-755. doi: 10.2967/jnumed.117.198085 |
|
2017 Journal Article Molecular imaging in the investigation of hypoglycaemic syndromes and their managementPattison, David A. and Hicks, Rodney J. (2017). Molecular imaging in the investigation of hypoglycaemic syndromes and their management. Endocrine-Related Cancer, 24 (6), R203-R221. doi: 10.1530/erc-17-0005 |
|
2026 Journal Article Predictive value of early PSMA upregulation for the response to enzalutamide ± <SUP>177</SUP>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialEmmett, Louise, Swiha, Mina, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn, Goh, Jeffrey, Pattison, David, Pathmanandavel, Sarennya, Hope, Thomas, Ayati, Narjess, Hofman, Michael, Sandhu, Shahneen, Niu, Claire, Martin, Andrew, Thomas, Hayley, Stockler, Martin and Davis, Ian (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nature Cancer, 7 (4), 622-630. doi: 10.1038/s43018-026-01140-3 |
|
2026 Journal Article <sup>177</sup> Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerAyati, Narjess, Papa, Nathan, Crumbaker, Megan, Subramaniam, Shalini, Joshua, Anthony M., Alipour, Ramin, Iravani, Amir, Askari, Emran, Khan, Sobia, Yadav, Surekha, Eiber, Matthias, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Nguyen, Andrew, Hofman, Michael S., Sandhu, Shahneen, Hioki, Takanori, van Oorschodt, Julian C. J., Devitt, Katrina, Willowson, Kathy, Sharma, Shikha, Stancu, Alexandru, Chauvie, Stephane ... on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319 (1) e252672. doi: 10.1148/radiol.252672 |
|
2025 Conference Publication Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trialHansen, A.R., Pattison, D.A., Gan, C.L., Goh, J.C.H., Ngai, S., Katchel, L., Holmes, I., Baker, S., Campbell, L., Brady, J., Santoro, P., Crumbaker, M., Baronet, M., Rose, S., Adamovich, A.A., Puttick, S., Kryza, T., Kuan, K., Karmann, A. and Wyld, D.K. (2025). Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial. ESMO Congress 2025, Berlin, Germany, 17-21 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2025.08.3004 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D, Stockler, Martin R and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Journal Article A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerRoberts, Matthew J., Roberts, Natasha A., Pelecanos, Anita, Yaxley, John W., Harley, Simon J. D., Siriwardana, Amila R., Cullen, Karla, Prior, Marita, Lindsay, Karen, Vela, Ian, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David A. (2025). A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Research, 15 (1) 92, 1-10. doi: 10.1186/s13550-025-01265-z |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in ProgressGoh, Jeffrey, Pattison, David, Ngai, Stanley, Katchel, Loren, Holmes, Ingrid, Baker, Sean, Biggs, Heather, Cuscaden, Claire, Campbell, Louise, Brady, Jasmine, Lindsay, Karen, Latter, Melissa, Griffiths, Matthew, O'Mahoney, Eoin, Dhiantravan, Nattakorn, Francis, Roslyn, Rose, Stephen, Soderholm, Amelia, Baronet, Meghan, Crumbaker, Megan, Kryza, Thomas, Shakti, Stelle, Naidoo, Sheruna, Puttick, Simon, Horsfall, Aimee, Barkhausen, Christoph, Kuan, Kevin, Santoro, Paola, Skingley, Lesley ... Hansen, Aaron (2025). Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in Progress. 2025 ANZUP Annual Scientific Meeting, Sydney, NSW Australia, 20-22 July 2025. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2025 Journal Article Peptide receptor radionuclide therapy in malignant insulinomaPattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018 |
|
2025 Conference Publication Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumoursBurge, Matthew E., Wyld, David, Pattison, David A., Bahamad, Sandra, Hayes, Sarah J., Kuszewski, Julia A., Chantrill, Lorraine A., Price, Timothy Jay, Wong, Hui-Li, Chan, David, Grover, Piyush, Michael, Michael, Siu, Derrick, Bishop, Christine, Barker, Daniel, Goodwin, Rachel Anne, O'Callaghan, Christopher J., Loree, Jonathan M. and Mak, W. John (2025). Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours. 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.tps4224 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E. P., van der Heijden, Erik H. F. M., Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A., Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, 1-10. doi: 10.1136/bmjresp-2024-002553 |
|
2025 Journal Article The Utah NeoSeq Project: a collaborative multidisciplinary program to facilitate genomic diagnostics in the neonatal intensive care unitJenkins, Sabrina Malone, Palmquist, Rachel N., Moore, Barry, Boyden, Steven E., Nicholas, Thomas J., Bayrak-Toydemir, Pinar, Mao, Rong, Farrell, J. Andrew R., Holt, Carson H., Rynearson, Shawn G., Solorzano, Chelsea M., Ward, Alistair, Best, D. Hunter, Al-Sweel, Najla, Bentley, Dawn L., Brunelli, Luca, Chow, Clement Y., Close, Devin W., Cormier, Michael J., Deshotel, Malia J., Durtschi, Jacob, Eide, Erik J., Floyd, Luaiva, Fredrickson, Eric K., Fulmer, Makenzie L., Hernandez, Edgar J., Kapron, Ashley L., Karren, Mary Anne, Lewis, Robert G. ... Bonkowsky, Joshua L. (2025). The Utah NeoSeq Project: a collaborative multidisciplinary program to facilitate genomic diagnostics in the neonatal intensive care unit. Npj Genomic Medicine, 10 (1) 26. doi: 10.1038/s41525-025-00483-7 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Conference Publication Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.17 |
